Evofem Biosciences, Inc. · OTC:EVFM

Evofem Biosciences — Investor Presentation (December 2020)

24 slides from Evofem Biosciences's investor presentation, Dec 1, 2020

1. Slide 1: Revolutionizing Women's Sexual and Reproductive Health

   1 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. Saundra Pelletier, CEO Revolutionizing Women’s Sexual and Reproductive Health NASDAQ: EVFM December 2020

2. Slide 2: Forward-Looking Statements

   2 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. Forward-Looking Statements This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, y

3. Slide 3: Evofem Biosciences 101

   3 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. Evofem Biosciences 101 • Commercial-stage biopharmaceutical company • Mission: to improve women’s lives by developing and commercializing innovative prescription products to address critical unmet needs in w

4. Slide 4: Strong and Experienced Leadership

   4 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. Strong and Experienced Leadership Saundra Pelletier Chief Executive Officer Jay File Chief Financial Officer Kelly Culwell, MD Chief Medical Officer Russ Barrans Chief Commercial Officer 7 years at Evofem 30

5. Slide 5: Over $1 Bn US Market Opportunity

   5 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. Sources: 1. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015-2017. NCHS Data Brief. 2018; 327: 1-14 2. Phexxi Forecast Model Assumption. There are 21 million women

6. Slide 6: First-in-class Vaginal pH Modulator

   6 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. First-in-class Vaginal pH Modulator1 • FDA-approved prescription contraceptive vaginal gel • Non-hormonal • Female-controlled & used on-demand • Bio-adhesive properties • Highly viscous • Maintains vaginal p

7. Slide 7: The Time is Right for Phexxi

   7 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. The Time is Right for Phexxi In the US today, there are 21 million women at risk for pregnancy who are NOT using hormonal contraception1 7 1. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015- 20

8. Slide 8: HCPs Recognize the Unmet Need for Prescription Non-Hormonal Options

   8 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. HCPs Recognize the Unmet Need for Prescription Non-Hormonal Options Source: KJT Group Phexxi HCP Segmentation Market Research – Q4 2018. n=1,024. Q340 Imagine Product X is now available. How many of your pat

9. Slide 9: Reaching HCPs with "Best in Class" Sales Team

   9 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. Reaching HCPs with “Best in Class” Sales Team 70 Women’s Health sales reps and regional managers • Average experience: 15 years in Pharma, 8 of which are women’s health o Existing relationships, credibility

10. Slide 10: Phexxi is Off to a Strong Start

    10 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. Phexxi® is Off to a Strong Start Building Awareness • 650,000 visits to consumer site1 • Strong engagement driving conversions on HCP-Phexxi.com o 31k unique visitors, 53k page views2 • Successfully harness

11. Slide 11: Phexxi Telehealth Platform is Exceeding Expectations

    11 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. Phexxi® Telehealth Platform is Exceeding Expectations 41% of women who qualified for Phexxi through our Phexxi Concierge Service have requested a Phexxi prescription Populus Media: “Phexxi is our most succe

12. Slide 12: Phexxi Concierge Recruitment Platform Driving Significant Leads

    12 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. Phexxi® Concierge Recruitment Platform with Nurse Support Driving Significant Leads Harnessing AI to generate high-quality leads • 83Bar metrics projected generation of 200 leads/month • Consistently genera

13. Slide 13: Phexxi is Off to a Strong Start

    13 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. Phexxi is Off to a Strong Start • Monthly prescriptions(TRx) increased 64% in October vs. September1 • 809 unique Phexxi prescribers2 o Geographically diverse • Over 33% of prescribers wrote multiple Phexxi

14. Slide 14: Market Access: Positive Coverage Trends

    14 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. • 55% of commercial lives covered • Unique classification in the payor-utilized pricing compendiums First Data Bank and Medispan as “Vaginal pH Modulator” allowing for favorable reimbursement • Phexxi on pr

15. Slide 15: Favorable Data from Post-Concierge Surveys

    15 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. Favorable Data from Post-Concierge Surveys Hormone-free Doesn't impact cycle In the moment Ease of use Product Attributes Underlying Decision to Move Forward with Phexxi1 Source: 83Bar 11 November 2020 1. Question 9: “Why did you decide

16. Slide 16: $2.3 Billion Peak Revenue Potential

    16 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. Sterilization, other non-targets - 32.5M Non-Rx Contraceptive Users 10.3M No Contraceptive - 10.6M Rx Contraceptive Users - 18.8M US Contraceptive Market: 72.2M Women1 $670M - $860M $375M - $690M Phexxi Pea

17. Slide 17: Pipeline: EVO100 for Prevention of Chlamydia and Gonorrhea in Women

    17 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. Pipeline: EVO100 for Prevention of Chlamydia and Gonorrhea in Women EVO100 is investigational and safety and efficacy have not been established.

18. Slide 18: STI Prevention: A Large Market Opportunity

    18 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. STI Prevention: A Large Market Opportunity Sources: 1. Based on US Census Projections, CDC Data Brief 327, primary market research data collected Q2 2020 2. US. 2018. Centers for Disease Control and Prevent

19. Slide 19: AMPREVENCE: Statistically Significant Results

    19 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. AMPREVENCE: Statistically Significant Results EVO100 Generally Safe & Well Tolerated Most side effects were mild to moderate • 20.8% of women experienced an AE • Few women discontinued due to AEs in either arm (EVO100, 1.1%; placebo, 1.5

20. Slide 20: EVOGUARD Phase 3 Trial Underway

    20 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. EVOGUARD Phase 3 Trial Underway • Phase 3, double-blind, placebo- controlled study • Enrolling 1,730 healthy women age ≥18 years o Urogenital CT and/or GC infection within 16 weeks prior to enrollment o 1 risk factor if infection documen

21. Slide 21: EVO100: Timeline to Approval

    21 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. EVO100: Timeline to Approval 1,2 2021 2022 2023 Potential US Approval & Commercial Launch NDA submission2 Top-Line Results1 Initiate Pivotal Phase 3 Trial • FDA Fast Track designation for prevention of chla

22. Slide 22: Financial Overview

    22 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. Financial Overview • Shares outstanding: 81.3M1 • Warrants outstanding: 10.4M2 oWeighted average exercise price $4.54 • Unrestricted cash: $86.7M2 o$25M in Oct. 2020 from Adjuvant Capital • Runway into 2H 2

23. Slide 23: Our Time is Now

    23 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc. For investor discussions only. Our Time is Now • Marketing Phexxi® as the first-and-only hormone-free, on- demand, woman-controlled contraceptive vaginal gel oOver $1 billion US market opportunity o21 million US women at risk for pregnan

24. Slide 24: 2020 Evofe Biosciences, Inc.

    24 ©2019 Evofem Biosciences, Inc. 2020 Evofe Biosciences, Inc.

Evofem Biosciences — Investor Presentation (December 2020) on 6ix